Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Kavanaugh

Showing results (51-60 of 381) with videos related to

Pageof 39
Sort By:
Pathophysiology : the Official Journal of the International Society for Pathophysiology|August 16, 2005
Novel therapies for rheumatoid arthritisJames Chang, Arthur Kavanaugh
Rheumatology (Oxford, England)|August 16, 2014
Psoriatic arthritis: current therapy and future approachesDoQuyen Huynh, Arthur Kavanaugh
Pharmacoeconomics|January 18, 2008
Economic burden of psoriatic arthritisChristoph Ackermann, Arthur Kavanaugh
Therapeutic Advances in Chronic Disease|July 3, 2015
Psoriatic arthritis: latest treatments and their place in therapyEun Jin Kang, Arthur Kavanaugh
The Journal of Allergy and Clinical Immunology|October 8, 2005
Adverse reactions to biologic agents: focus on autoimmune disease therapiesSusan J Lee, Arthur Kavanaugh
Expert Opinion on Drug Safety|March 30, 2005
What to do with TNF failuresEdward C Keystone, Arthur Kavanaugh
Expert Review of Clinical Immunology|September 18, 2018
Golimumab in the treatment of psoriatic arthritisThorvardur Jon Love, Arthur Kavanaugh
The Journal of Allergy and Clinical Immunology|February 4, 2006
4. Autoimmunity, vasculitis, and autoantibodiesSusan J Lee, Arthur Kavanaugh
Clinical and Experimental Rheumatology|October 17, 2013
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trialsArthur Kavanaugh, Josef S Smolen
Rheumatology (Oxford, England)|April 15, 2014
Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritisArthur Kavanaugh, Alvin F Wells
Pageof 39

Showing results (51-60 of 381) with videos related to

Sort By:
Pageof 39
Pathophysiology : the Official Journal of the International Society for Pathophysiology|August 16, 2005
Novel therapies for rheumatoid arthritisJames Chang, Arthur Kavanaugh
Rheumatology (Oxford, England)|August 16, 2014
Psoriatic arthritis: current therapy and future approachesDoQuyen Huynh, Arthur Kavanaugh
Pharmacoeconomics|January 18, 2008
Economic burden of psoriatic arthritisChristoph Ackermann, Arthur Kavanaugh
Therapeutic Advances in Chronic Disease|July 3, 2015
Psoriatic arthritis: latest treatments and their place in therapyEun Jin Kang, Arthur Kavanaugh
The Journal of Allergy and Clinical Immunology|October 8, 2005
Adverse reactions to biologic agents: focus on autoimmune disease therapiesSusan J Lee, Arthur Kavanaugh
Expert Opinion on Drug Safety|March 30, 2005
What to do with TNF failuresEdward C Keystone, Arthur Kavanaugh
Expert Review of Clinical Immunology|September 18, 2018
Golimumab in the treatment of psoriatic arthritisThorvardur Jon Love, Arthur Kavanaugh
The Journal of Allergy and Clinical Immunology|February 4, 2006
4. Autoimmunity, vasculitis, and autoantibodiesSusan J Lee, Arthur Kavanaugh
Clinical and Experimental Rheumatology|October 17, 2013
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trialsArthur Kavanaugh, Josef S Smolen
Rheumatology (Oxford, England)|April 15, 2014
Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritisArthur Kavanaugh, Alvin F Wells
Pageof 39